<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100735">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01791959</url>
  </required_header>
  <id_info>
    <org_study_id>046466</org_study_id>
    <nct_id>NCT01791959</nct_id>
  </id_info>
  <brief_title>The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <authority>IRAN: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory
      factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50
      patients who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be
      randomly allocated to receive 2 protexin capsules or placebos for 7 months; both groups will
      be advised to adherence our diet and exercise program too. At the first and the end of the
      intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis
      will be assessed and compared between groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Alaninaminotransferase  (ALT)</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 synbiotic capsules for 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodexterin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>two capsules per day for 28 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>synbiotic</intervention_name>
    <description>2 symbiotics capsules per day for 28 weeks</description>
    <arm_group_label>Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>2 Maltodexterin capsules  as a placebo per day for 28 weeks</description>
    <arm_group_label>maltodexterin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 to 70 years

          -  Body Mass Index (BMI) between 25-40

          -  Serum alaninaminotransferase more than 1.5 fold of upper limit of normal range

          -  Sonographic findings compatible with hepatic steatosis (degree 2 or more)

        Exclusion Criteria:

          -  Diabetes

          -  Taking any kind of antibiotics two weeks before recruitment

          -  History of alcohol consumption

          -  pregnancy or lactation

          -  Professional athletes

          -  Other liver disease (viral/etc)

          -  Use of drugs such as calcium channel blockers, high dose synthetic estrogens,
             methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs,
             lipid-lowering agents, metformin and vitamin E

          -  A history of Hypertension, Cardiovascular disease, Pulmonary disease, Renal disease &amp;
             Celiac disease; Cirrhosis

          -  History of Upper GI surgery / Prior surgical procedures such as jejunoileal or
             jejunocolic bypass, gastroplasty

          -  Following program to lose weight in recent 3 mo

          -  A history of hypothyroidism or Cushing's syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azita Hekmatdoost, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Nutrition and Food Technology Research Institute</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 12, 2013</lastchanged_date>
  <firstreceived_date>February 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>Dr Azita Hekmatdoost</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
